Saturday, April 13, 2019 9:28:12 PM
2017
At the end of 2017 the ticker was trading at $6+ range (click on 2 year chart).
https://ih.advfn.com/stock-market/USOTC/gex-management-inc-GXXM/stock-price#2y
The OS shares was 11.36 million according to 10K for 2017 and the company was generating revenues around $8.3 million, click link (page 28).
https://www.otcmarkets.com/filing/conv_pdf?id=12677847&guid=QYZ3UHdxdvn8zyh
So average MC 2017 (approximating $6 dollar PPS) = $6 X 11.36 = $68 million.
Current Status
The OS has increased 30 times, now at 348.6 million, the MC = $1.3 million (as per OTC). Applying the same MC as it was in 2017 but to the current OS:
PPS estimates = ($68 million/348.6 OS) = .195 cents PPS. Therefore, adjusting for dilution and using the 2017 MC, the PPS estimate (.195 cents) is way higher than the current double zero PPS (.0037).
Also noted, the 2018 revenue is expected to be at $12+ million compared to $8.3 million in 2017.
And then the potential merger/buyout scenario, which could be very beneficial by itself.
The extent of conversion/dilution still remains in the pipeline (maybe not much, We don't know) will also be an important determining factor for PPS going forward.
I like my chances here, glad loaded my boat.
Best of luck to all for whatever is your decision.
$GXXM$
Disclosure: My posts are just my opinion, not intended for investment advice. Do your own DD.
Recent GXXM News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:15:53 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 11/13/2023 09:11:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/01/2023 08:38:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:22:30 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 08/21/2023 08:00:34 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 02:09:47 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM